Ruxolitinib for the treatment of graft-versus-host disease.

ABSTRACTIntroduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythem...